[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

AR006250A1 - Compuestos y metodos para la inmunoterapia e inmunodiagnostico del cancer prostatico - Google Patents

Compuestos y metodos para la inmunoterapia e inmunodiagnostico del cancer prostatico

Info

Publication number
AR006250A1
AR006250A1 ARP970101046A ARP970101046A AR006250A1 AR 006250 A1 AR006250 A1 AR 006250A1 AR P970101046 A ARP970101046 A AR P970101046A AR P970101046 A ARP970101046 A AR P970101046A AR 006250 A1 AR006250 A1 AR 006250A1
Authority
AR
Argentina
Prior art keywords
polypeptides
compounds
methods
immunotherapy
presented
Prior art date
Application number
ARP970101046A
Other languages
English (en)
Original Assignee
Corixa Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corixa Corp filed Critical Corixa Corp
Publication of AR006250A1 publication Critical patent/AR006250A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Veterinary Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Plant Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)

Abstract

Se presentan compuestos y métodos para el tratamiento y diagnóstico del cáncer de próstata. Los compuestos incluyen polipéptidos que contienenpor lo menos una porción de una proteina postática. También se presentan vacunas y composicionesfarmacéuticas para la inmunoterapia del cáncer depróstata que comprenden tales polipétpidos o moléculas de ADN que codifican tales polipéptidos. Los polipéptidos también pueden utilizar para generaranticuerpos útiles para el diagnóstico y monitoreo del cáncer de próstata. Se presentan además secuencias de ácidos nucleicos para preparar sondas,cebadores y polipéptidos.
ARP970101046A 1996-03-15 1997-03-14 Compuestos y metodos para la inmunoterapia e inmunodiagnostico del cancer prostatico AR006250A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61674596A 1996-03-15 1996-03-15
US63384096A 1996-04-11 1996-04-11

Publications (1)

Publication Number Publication Date
AR006250A1 true AR006250A1 (es) 1999-08-11

Family

ID=27087847

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP970101046A AR006250A1 (es) 1996-03-15 1997-03-14 Compuestos y metodos para la inmunoterapia e inmunodiagnostico del cancer prostatico

Country Status (11)

Country Link
US (1) US6034218A (es)
EP (1) EP0914335A2 (es)
KR (1) KR19990087802A (es)
AR (1) AR006250A1 (es)
AU (1) AU728186B2 (es)
BR (1) BR9708082A (es)
CA (1) CA2249742A1 (es)
CO (1) CO4600637A1 (es)
NO (1) NO984229L (es)
NZ (1) NZ331866A (es)
WO (1) WO1997033909A2 (es)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6290969B1 (en) * 1995-09-01 2001-09-18 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
US6592877B1 (en) * 1995-09-01 2003-07-15 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
US6458366B1 (en) 1995-09-01 2002-10-01 Corixa Corporation Compounds and methods for diagnosis of tuberculosis
SE520392C2 (sv) 1996-09-27 2003-07-01 Creative Peptides Sweden Ab C Specifika peptider för behandling av diabetes mellitus
US20030185830A1 (en) 1997-02-25 2003-10-02 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6620922B1 (en) 1997-02-25 2003-09-16 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6894146B1 (en) 1997-02-25 2005-05-17 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6943236B2 (en) 1997-02-25 2005-09-13 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6759515B1 (en) 1997-02-25 2004-07-06 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6818751B1 (en) 1997-08-01 2004-11-16 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US7202342B1 (en) 1999-11-12 2007-04-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6630305B1 (en) 1999-11-12 2003-10-07 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6465611B1 (en) 1997-02-25 2002-10-15 Corixa Corporation Compounds for immunotherapy of prostate cancer and methods for their use
US7517952B1 (en) 1997-02-25 2009-04-14 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US7033827B2 (en) 1997-02-25 2006-04-25 Corixa Corporation Prostate-specific polynucleotide compositions
US6800746B2 (en) 1997-02-25 2004-10-05 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6613872B1 (en) 1997-02-25 2003-09-02 Corixa Corporation Compounds for immunotherapy of prostate cancer and methods for their use
CZ298465B6 (cs) 1997-02-25 2007-10-10 Corixa Corporation Polypeptid, molekula DNA, expresní vektor, hostitelská bunka, farmaceutický prostredek, vakcína a fúzní protein
US6329505B1 (en) 1997-02-25 2001-12-11 Corixa Corporation Compositions and methods for therapy and diagnosis of prostate cancer
US6395278B1 (en) 1997-02-25 2002-05-28 Corixa Corporation Prostate specific fusion protein compositions
US6261562B1 (en) 1997-02-25 2001-07-17 Corixa Corporation Compounds for immunotherapy of prostate cancer and methods for their use
US6555653B2 (en) * 1997-05-20 2003-04-29 Corixa Corporation Compounds for diagnosis of tuberculosis and methods for their use
AU9689398A (en) * 1997-10-07 1999-04-27 Corixa Corporation Compounds and methods for immunotherapy and immunodiagnosis of prostate cancer
AU2474699A (en) * 1998-01-26 1999-08-09 Genquest Inc. Compositions and methods for detecting and treating prostate cancer
EP1870466A3 (en) * 1998-07-14 2008-03-19 Corixa Corporation Compositions and methods for therapy and diagnosis of prostate cancer
US6458925B1 (en) 1998-08-03 2002-10-01 University Of Maryland, Baltimore Peptide antagonists of zonulin and methods for use of the same
US6387888B1 (en) 1998-09-30 2002-05-14 American Foundation For Biological Research, Inc. Immunotherapy of cancer through expression of truncated tumor or tumor-associated antigen
GB9828840D0 (en) * 1998-12-30 1999-02-17 Univ Nottingham Trent Prostate cancer associated genes and their products
US8143386B2 (en) * 1999-04-07 2012-03-27 Corixa Corporation Fusion proteins of mycobacterium tuberculosis antigens and their uses
AU5173400A (en) * 1999-05-28 2000-12-18 Sugen, Inc. Protein kinases
WO2001005968A1 (en) * 1999-06-21 2001-01-25 Inkine Pharmaceutical Company, Inc. Angiocidin: a cys-ser-val-thr-cys-gly specific tumor cell adhesion receptor
US20020058292A1 (en) * 2000-12-08 2002-05-16 Dillon Davin C. Ovarian tumor antigen and methods of use therefor
US7311922B1 (en) * 1999-10-07 2007-12-25 Corixa Corporation Fusion proteins of mycobacterium tuberculosis
AU1656501A (en) * 1999-11-12 2001-06-06 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
EP1261708A2 (en) * 2000-01-14 2002-12-04 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
AU2001241738A1 (en) 2000-02-25 2001-09-03 Corixa Corporation Compounds and methods for diagnosis and immunotherapy of tuberculosis
CA2444607A1 (en) * 2000-04-26 2001-11-01 The Scripps Research Institute Pancreatic progenitor 1 gene and its uses
PT1542732E (pt) * 2000-06-20 2009-11-06 Corixa Corp Proteínas de fusão de mycobacterium tuberculosis
ATE470716T1 (de) * 2000-07-18 2010-06-15 Millennium Pharm Inc 18480 humane proteinkinasemoleküle und ihre verwendungen
AU2001279082A1 (en) * 2000-07-31 2002-02-13 Gene Logic, Inc. Expression of gage/page-like protein in benign prostatic hyperplasia
US7048931B1 (en) 2000-11-09 2006-05-23 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
HUP0303905A3 (en) 2000-11-28 2005-11-28 Wyeth Corp Expression analysis of kiaa nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
IL155952A0 (en) 2000-11-28 2003-12-23 Wyeth Corp Expression analysis of fkbp nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
IL155954A0 (en) * 2000-11-28 2003-12-23 Wyeth Corp Expression analysis of smarc nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
CA2439442A1 (en) * 2001-02-26 2002-09-06 Xianghe Yan Isolated human protease proteins, nucleic acid molecules encoding human protease proteins, and uses thereof
JP2005505242A (ja) * 2001-03-07 2005-02-24 マンカインド コーポレイション 癌用抗新生血管系調製物
US20030118585A1 (en) * 2001-10-17 2003-06-26 Agy Therapeutics Use of protein biomolecular targets in the treatment and visualization of brain tumors
EP1402031A2 (en) 2001-06-21 2004-03-31 Isis Innovation Limited Atopy
JP4491567B2 (ja) * 2001-07-19 2010-06-30 財団法人新産業創造研究機構 ヒト由来のスフィンゴシン・キナーゼ１に結合する新規タンパク質、及び当該タンパク質をコードするポリヌクレオチド
US8507445B2 (en) * 2001-09-07 2013-08-13 Board Of Regents, The University Of Texas System Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer
WO2003070187A2 (en) * 2002-02-15 2003-08-28 Corixa Corporation Fusion proteins of mycobacterium tuberculosis
DE10217254A1 (de) 2002-04-15 2003-10-23 Proteosys Ag Verwendung von Substanzen zur Behandlung von Tumoren
WO2006023598A2 (en) * 2004-08-19 2006-03-02 University Of Maryland, Baltimore Prostate-specific antigen-derived mhc class ii-restricted peptides and their use in vaccines to treat or prevent prostate cancer
US9957569B2 (en) * 2005-09-12 2018-05-01 The Regents Of The University Of Michigan Recurrent gene fusions in prostate cancer
JP5512125B2 (ja) * 2005-09-12 2014-06-04 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 前立腺癌における再発性遺伝子融合
CA2638914C (en) 2006-02-09 2014-04-08 Alba Therapeutics Corporation Formulations for a tight junction effector
JP5244103B2 (ja) * 2006-08-09 2013-07-24 ホームステッド クリニカル コーポレイション 器官特異的蛋白質およびその使用方法
WO2008043107A2 (en) 2006-10-06 2008-04-10 Alba Therapeutics Corporation Use of tight junction antagonists to treat inflammatory bowel disease
US8034776B2 (en) 2006-10-26 2011-10-11 Alba Therapeutics Corporation Materials and methods for the treatment of celiac disease
EP2079851B1 (en) * 2006-11-08 2015-01-07 The Regents Of The University Of Michigan Method using spink1 as a prostate cancer marker
US9962424B2 (en) * 2007-04-27 2018-05-08 Lantmännen As-Faktor Ab Use of antisecretory factors (AF) for optimizing cellular uptake
WO2009009431A2 (en) * 2007-07-06 2009-01-15 The Regents Of The University Of Michigan Mipol1-etv1 gene rearrangements
WO2009009432A2 (en) 2007-07-06 2009-01-15 The Regents Of The University Of Michigan Recurrent gene fusions in prostate cancer
CA2695674A1 (en) 2007-08-16 2009-02-26 Metabolon, Inc. Metabolomic profiling of prostate cancer
US20110136683A1 (en) 2008-05-28 2011-06-09 Genomedx Biosciences, Inc. Systems and Methods for Expression-Based Discrimination of Distinct Clinical Disease States in Prostate Cancer
KR20110111474A (ko) 2009-01-09 2011-10-11 더 리젠츠 오브 더 유니버시티 오브 미시간 암에서의 반복적 유전자 융합체
US20100311815A1 (en) * 2009-02-23 2010-12-09 The Regents Of The University Of Michigan Mir-101 cancer markers
CN102712953A (zh) * 2009-09-17 2012-10-03 密歇根大学董事会 前列腺癌中的复发性基因融合物
US20150284802A1 (en) 2010-11-19 2015-10-08 The Regents Of The University Of Michigan ncRNA AND USES THEREOF
US8945556B2 (en) 2010-11-19 2015-02-03 The Regents Of The University Of Michigan RAF gene fusions
EP3435084B1 (en) 2012-08-16 2023-02-22 Decipher Biosciences, Inc. Prostate cancer prognostics using biomarkers
EP3243077B1 (en) 2015-01-05 2019-09-04 University Of Oslo Prostate cancer markers and uses thereof
AU2017315425B2 (en) 2016-08-24 2023-11-09 The Regents Of The University Of Michigan Use of genomic signatures to predict responsiveness of patients with prostate cancer to post-operative radiation therapy
WO2018132916A1 (en) 2017-01-20 2018-07-26 Genomedx Biosciences, Inc. Molecular subtyping, prognosis, and treatment of bladder cancer
WO2018165600A1 (en) 2017-03-09 2018-09-13 Genomedx Biosciences, Inc. Subtyping prostate cancer to predict response to hormone therapy
CA3062716A1 (en) 2017-05-12 2018-11-15 Decipher Biosciences, Inc. Genetic signatures to predict prostate cancer metastasis and identify tumor agressiveness

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990009446A1 (en) * 1989-02-17 1990-08-23 Plant Genetic Systems N.V. Cutinase
ATE342356T1 (de) * 1992-11-05 2006-11-15 Sloan Kettering Inst Cancer Prostata-spezifisches membranantigen
AU686660B2 (en) * 1993-08-11 1998-02-12 Jenner Technologies Prostatic cancer vaccine

Also Published As

Publication number Publication date
EP0914335A2 (en) 1999-05-12
CA2249742A1 (en) 1997-09-18
AU728186B2 (en) 2001-01-04
BR9708082A (pt) 1999-07-27
NO984229D0 (no) 1998-09-14
CO4600637A1 (es) 1998-05-08
US6034218A (en) 2000-03-07
WO1997033909A2 (en) 1997-09-18
WO1997033909A3 (en) 1997-12-24
NZ331866A (en) 2000-05-26
AU2329597A (en) 1997-10-01
KR19990087802A (ko) 1999-12-27
NO984229L (no) 1998-11-13

Similar Documents

Publication Publication Date Title
AR006250A1 (es) Compuestos y metodos para la inmunoterapia e inmunodiagnostico del cancer prostatico
EA200101037A1 (ru) Соединения и способы для лечения и диагностики рака легкого
AR038568A1 (es) Anticuerpos anti-a beta y su uso
BR9908823A (pt) Compostos e processos para terapia e diagnóstico de câncer de pulmão
BR9807734A (pt) Composto para imunodiagnose de câncer de próstata e métodos para o uso dos memos
HUP0002095A2 (hu) Vegyületek prosztatarák immunterápiás kezelésére és alkalmazásuk
EA200501206A1 (ru) Производные от сурвивина пептиды и их применение
TW581808B (en) Compounds for immunotherapy of prostate cancer and methods for their use
MXPA02011656A (es) Moleculas de acido nucleico nrg-2, polipeptidos, y metodos de diagnostico y terapeuticos.
ATE410446T1 (de) Zusammensetzungen zur behandlung und diagnose von eierstockkrebs
AR033978A1 (es) Molecula de anticuerpo con especificidad para factor de necrosis tumoral alfa humano y usos de las mismas
DE69703121D1 (de) Verfahren und zusammensetzungen zur verhinderung von entzündungen und angiogenese enthaltend säugetieren cd97 alpha untereinheit
ATE303161T1 (de) Humanisierung von anti-carcinoembryonalen antigen anti-idiotypischen antikörper und dessen verwendung als tumorvakzin und zur markierung
CY1113421T1 (el) Πυρηνικα οξεα και πολυπεπτιδια υποδοχεα
CY1109699T1 (el) Νουκλεινικα οξεα που κωδικοποιουν πολυπεπτιδια πολυεπιτοπων
DE69630457D1 (de) Verbindungen zur immunotherapie und diagnose von tuberkulose
ES2054612T3 (es) Secuencias de adn que codifican para proteinas con actividad biologica de los inhibidores husi tipo-i y procedimientos tecnologicos geneticos para la preparacion de estas proteinas.
BR0009608A (pt) Compostos para imunoterapia e diagnóstico de câncer de mama e métodos para sua utilização
ES2141249T3 (es) Procedimiento para la identificacion de celulas humanas y animales que presentan la capacidad para una proliferacion ilimitada o para una formacion de tumores.
DK1082423T3 (da) Cyclin E2-gener og -proteiner
DK1352056T3 (da) Polypeptider, der er i stand til at fremkalde en immunreaktion mod cancer
WO1999018210A3 (en) Compounds and methods for immunotherapy and immunodiagnosis of prostate cancer
UY26170A1 (es) Antigeno (c42) asociados a tumores
AR023794A1 (es) Antigeno asociado con tumores
CO5050254A1 (es) Compuestos para el tratamiento y diagnostico del cancer de pulmon